Role of intravenous tranexamic acid for the reduction of blood loss in total knee arthroplasty

Abstract

Antifibrinolytic drug Tranexamic acid (TXA) administered intravenously has shown to significantly reduced the blood loss intraoperatively (P<0.01) and postoperatively (P<0.01) in patients undergoing bilateral total knee arthroplasty. Two groups of 50 patients each with similar demographic and health profile were selected to undergo this study. One group received the IV Tranexamic Acid (TXA group) while the control group did not received. To avoid complications associated with antifibrinolytic property of tranexamic acid. Strict patient selection criteria and dose regiment protocols were adhered to prevent hypercoagulable state with potential risk of DVT and renal Failure.